– NASDAQ:DBVT
stock price today
$9.64
+6.45
+202.19%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
stock price monthly change
+298.75%
month
stock price quarterly change
+298.75%
quarter
stock price yearly change
+206.73%
year
key metrics
Market Cap | 65.63M |
Enterprise value | N/A |
P/E | -2.71 |
EV/Sales | N/A |
EV/EBITDA | 0.17 |
Price/Sales | N/A |
Price/Book | 0.94 |
PEG ratio | -0.08 |
EPS | -0.83 |
Revenue | 14.97M |
EBITDA | -73.54M |
Income | -79.47M |
Revenue Q/Q | -35.87% |
Revenue Y/Y | 233.18% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -491.27% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freestock price history
stock forecast
financial statements
| Jun 2023 | 2.28M | -24.24M | -1059.57% |
|---|---|---|---|
| Sep 2023 | 2.4M | -16.7M | -695.83% |
| Dec 2023 | 8.87M | -11.18M | -126.04% |
| Mar 2024 | 1.40M | -27.34M | -1943.5% |
| 2025 | 5.31M | -98.65M | -1856.29% |
|---|---|---|---|
| 2026 | 23.63M | -82.13M | -347.57% |
| 2027 | 136.93M | -34.76M | -25.39% |
| 2028 | 294.51M | 114.73M | 38.96% |
Analysts Price target
Financials & Ratios estimates
| 2024-05-07 | -0.44 | -0.28 |
|---|
| Jun 2023 | 217518000 | 53.27M | 24.49% |
|---|---|---|---|
| Sep 2023 | 189800000 | 45.8M | 24.13% |
| Dec 2023 | 182986000 | 42.8M | 23.39% |
| Mar 2024 | 145895000 | 34.24M | 23.47% |
| Jun 2023 | -25.55M | -341K | 7.80M |
|---|---|---|---|
| Sep 2023 | -19.57M | -322K | -837K |
| Dec 2023 | -13.68M | -187K | -189K |
| Mar 2024 | -34.69M | -2.13M | -61.99K |
alternative data
| Aug 2023 | 85 |
|---|---|
| Sep 2023 | 88 |
| Oct 2023 | 88 |
| Nov 2023 | 88 |
| Dec 2023 | 97 |
| Jan 2024 | 97 |
| Feb 2024 | 97 |
| Mar 2024 | 104 |
| Apr 2024 | 104 |
| May 2024 | 104 |
| Jun 2024 | 105 |
| Jul 2024 | 105 |
other data
5.52%
-51.72%
of DBVT is owned by hedge funds
20
-18
4.27M
-49.47M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 1825 | 0 |
| Mar 2024 | 17094 | 0 |
| May 2024 | 0 | 1042 |
| Jul 2024 | 0 | 1785 |
| Nov 2024 | 0 | 3257 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | MOHIDEEN PHARIS officer: Chief Me.. | Ordinary Shares | 565 | $0.57 | $322 | ||
Sale | MOHIDEEN PHARIS officer: Chief Me.. | Ordinary Shares | 342 | $0.53 | $181 | ||
Sale | MOHIDEEN PHARIS officer: Chief Me.. | Ordinary Shares | 2,350 | $0.54 | $1,269 | ||
Sale | MOHIDEEN PHARIS officer: Chief Me.. | Ordinary Shares | 1,785 | $0.98 | $1,749 | ||
Sale | MOHIDEEN PHARIS officer: Chief Me.. | Ordinary Shares | 660 | $1.36 | $898 | ||
Sale | MOHIDEEN PHARIS officer: Chief Me.. | Ordinary Shares | 382 | $1.38 | $527 | ||
Purchase | TASSE DANIEL director, officer: CHIEF EXECUT.. | Ordinary Shares | 17,094 | $0.83 | $14,188 | ||
Purchase | NDU ADORA director | Ordinary Shares | 1,825 | $0.89 | $1,624 | ||
Sale | MOHIDEEN PHARIS officer: Chief Me.. | Ordinary Shares | 2,245 | $1.74 | $3,906 | ||
Purchase | MORRIS TIMOTHY E director | Ordinary Shares | 12,000 | $1.52 | $18,240 |
| Quarter | Transcript |
|---|---|
| Q4 2023 7 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 31 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 31 Jul 2023 | Q2 2023 Earnings Call Transcript |
| Q4 2022 3 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Daniel Tassé (1960) Chief Executive Officer & Director | $1,100,000 |
| Dr. Pharis Mohideen (1965) Chief Medical Officer | $625,260 |
Mr. SĂ©bastien Robitaille (1970) Chief Financial Officer | $291,820 |
-
What's the price of stock today?
One share of stock can currently be purchased for approximately $9.64.
-
When is 's next earnings date?
Unfortunately, 's (DBVT) next earnings date is currently unknown.
-
Does pay dividends?
No, does not pay dividends.
-
How much money does make?
has a market capitalization of 65.63M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 227.67% to 15.73M US dollars. made a loss 72.73M US dollars in net income (profit) last year or -$0.28 on an earnings per share basis.
-
What is 's stock symbol?
null is traded on the NASDAQ under the ticker symbol "DBVT".
-
What is 's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ?
Shares of can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are 's key executives?
's management team includes the following people:
- Mr. Daniel Tassé Chief Executive Officer & Director(age: 65, pay: $1,100,000)
- Dr. Pharis Mohideen Chief Medical Officer(age: 60, pay: $625,260)
- Mr. SĂ©bastien Robitaille Chief Financial Officer(age: 55, pay: $291,820)
-
How many employees does have?
As Jul 2024, employs 105 workers, which is 1% more then previous quarter.
-
When went public?
null is publicly traded company for more then 10 years since IPO on 22 Oct 2014.
-
What is 's official website?
The official website for is dbv-technologies.com.
-
How can i contact ?
can be reached via phone at +33 1 55 42 78 78.
company profile:
Exchange:
NASDAQ
Full time employees:
108
Industry:
Biotechnology
Sector:
Healthcare
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
177-181 Avenue Pierre Brossolette
Montrouge, 92120
Montrouge, 92120
CIK: 0001613780
ISIN: US23306J1016
CUSIP: 23306J101
